Split (1)

train · 34.2k rows

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.

instruction stringlengths 203 9.68k	response stringlengths 0 20.5k	output stringlengths 0 20.5k
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: Vorinostat? [/INST]	'Alternate Name': Vorinostat, 'Primary Sites': advanced solid tumors;colorectal;CTCL;Leukemia;other cancer, 'Category': Chemotherapy, 'Remarks': Phase I colorectal, advanced solid tumors 2007 Merck, Aton Pharma. FDA fast track and orphan status 2006 for CTCL. HDAC inhibitor	'Alternate Name': Vorinostat, 'Primary Sites': advanced solid tumors;colorectal;CTCL;Leukemia;other cancer, 'Category': Chemotherapy, 'Remarks': Phase I colorectal, advanced solid tumors 2007 Merck, Aton Pharma. FDA fast track and orphan status 2006 for CTCL. HDAC inhibitor
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: WF10? [/INST]	'Alternate Name': WF10, 'Primary Sites': Lymphoma, 'Category': AIDS drug, 'Remarks': Phase II Dimehaid Research, OXO Chemie.	'Alternate Name': WF10, 'Primary Sites': Lymphoma, 'Category': AIDS drug, 'Remarks': Phase II Dimehaid Research, OXO Chemie.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: WT-1 peptide vaccine? [/INST]	'Alternate Name': WT-1 peptide vaccine, 'Primary Sites': Pleura, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': March 4, 2016: The FDA granted Orphan Drug designation to the WT! Cancer Vaccine developed by SELLAS Life Science Group for the treatment of patients with malignant pleural mesothelioma. This was based on the positive results from phase II clinical trials. Phase IIb/III trials will be initiated. CODING: code this vaccine in Other Treatment, assign code 2	'Alternate Name': WT-1 peptide vaccine, 'Primary Sites': Pleura, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': March 4, 2016: The FDA granted Orphan Drug designation to the WT! Cancer Vaccine developed by SELLAS Life Science Group for the treatment of patients with malignant pleural mesothelioma. This was based on the positive results from phase II clinical trials. Phase IIb/III trials will be initiated. CODING: code this vaccine in Other Treatment, assign code 2
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: WX-UK1? [/INST]	'Alternate Name': WX-UK1, 'Primary Sites': Gastric;ovarian;pancreatic cancer, 'Category': Chemotherapy, 'Remarks': Phase I/II Urokinase inhibitor. Wilex.	'Alternate Name': WX-UK1, 'Primary Sites': Gastric;ovarian;pancreatic cancer, 'Category': Chemotherapy, 'Remarks': Phase I/II Urokinase inhibitor. Wilex.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: XIAP antisense? [/INST]	'Alternate Name': XIAP antisense, 'Primary Sites': AML, 'Category': Chemotherapy, 'Remarks': Phase II AML 2007 XIAP (X-linked Inhibitor-of-Apoptosis); apoptosis inducer. Aegera Therapeutics	'Alternate Name': XIAP antisense, 'Primary Sites': AML, 'Category': Chemotherapy, 'Remarks': Phase II AML 2007 XIAP (X-linked Inhibitor-of-Apoptosis); apoptosis inducer. Aegera Therapeutics
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: XK-469? [/INST]	'Alternate Name': XK-469, 'Primary Sites': Other cancer, 'Category': Chemotherapy, 'Remarks': Phase I NCI, Bristol-Myers Squibb.	'Alternate Name': XK-469, 'Primary Sites': Other cancer, 'Category': Chemotherapy, 'Remarks': Phase I NCI, Bristol-Myers Squibb.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: XK469? [/INST]	'Alternate Name': XK469, 'Primary Sites': advanced solid tumors;Lymphoma, 'Category': Chemotherapy, 'Remarks': Phase I lymphoma; advanced solid tumors 2007 Information from NCI	'Alternate Name': XK469, 'Primary Sites': advanced solid tumors;Lymphoma, 'Category': Chemotherapy, 'Remarks': Phase I lymphoma; advanced solid tumors 2007 Information from NCI
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: XL-139? [/INST]	'Alternate Name': XL-139, 'Primary Sites': GE and esophageal adenocarcinoma;inoperable stomach;mets gastric;multiiple myeloma;SCLC, 'Category': Chemotherapy, 'Remarks': I New drug currently in trials, code in other therapy	'Alternate Name': XL-139, 'Primary Sites': GE and esophageal adenocarcinoma;inoperable stomach;mets gastric;multiiple myeloma;SCLC, 'Category': Chemotherapy, 'Remarks': I New drug currently in trials, code in other therapy
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: XL-147? [/INST]	'Alternate Name': XL-147, 'Primary Sites': Advanced Endometrium;lymphoma;Mets breast;NSCLC;ovarian, 'Category': Chemotherapy, 'Remarks': New drug currently in trials, code in other therapy	'Alternate Name': XL-147, 'Primary Sites': Advanced Endometrium;lymphoma;Mets breast;NSCLC;ovarian, 'Category': Chemotherapy, 'Remarks': New drug currently in trials, code in other therapy
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: XL-184? [/INST]	'Alternate Name': XL-184, 'Primary Sites': GBM;NSCLC;solid tumors;Thyroid, 'Category': Chemotherapy, 'Remarks': I, II, III New drug currently in trials, code in other therapy	'Alternate Name': XL-184, 'Primary Sites': GBM;NSCLC;solid tumors;Thyroid, 'Category': Chemotherapy, 'Remarks': I, II, III New drug currently in trials, code in other therapy
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: XL-281? [/INST]	'Alternate Name': XL-281, 'Primary Sites': colorectal;melanoma;NSC;papillary thyroid, 'Category': Chemotherapy, 'Remarks': I, II New drug currently in trials, code in other therapy	'Alternate Name': XL-281, 'Primary Sites': colorectal;melanoma;NSC;papillary thyroid, 'Category': Chemotherapy, 'Remarks': I, II New drug currently in trials, code in other therapy
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: XL-765? [/INST]	'Alternate Name': XL-765, 'Primary Sites': breast;Malignant glioma;NSCLC, 'Category': Chemotherapy, 'Remarks': I, II New drug currently in trials, code in other therapy	'Alternate Name': XL-765, 'Primary Sites': breast;Malignant glioma;NSCLC, 'Category': Chemotherapy, 'Remarks': I, II New drug currently in trials, code in other therapy
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: XL-888? [/INST]	'Alternate Name': XL-888, 'Primary Sites': Failed first course;melanoma;mets;NSCLC;or unresectable: breast, 'Category': Chemotherapy, 'Remarks': I New drug currently in trials, code in other therapy	'Alternate Name': XL-888, 'Primary Sites': Failed first course;melanoma;mets;NSCLC;or unresectable: breast, 'Category': Chemotherapy, 'Remarks': I New drug currently in trials, code in other therapy
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: Xalkori? [/INST]	'Alternate Name': Xalkori, 'Primary Sites': Non Small Cell Lung Cancer (NSCLC), 'Category': Chemotherapy, 'Remarks': July 14, 2022, the Food and Drug Administration approved crizotinib (Xalkori) for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). January 14, 2021, the FDA approved crizotinib (Xalkori) for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL March 11, 2016 FDA approved crizotinib capsules (Xalkori, Pfizer, Inc.) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. Crizotinib received FDA approval 8/26/11 for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase-positive as detected by an FDA-approved test.	'Alternate Name': Xalkori, 'Primary Sites': Non Small Cell Lung Cancer (NSCLC), 'Category': Chemotherapy, 'Remarks': July 14, 2022, the Food and Drug Administration approved crizotinib (Xalkori) for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). January 14, 2021, the FDA approved crizotinib (Xalkori) for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL March 11, 2016 FDA approved crizotinib capsules (Xalkori, Pfizer, Inc.) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. Crizotinib received FDA approval 8/26/11 for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase-positive as detected by an FDA-approved test.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: Xcellerate? [/INST]	'Alternate Name': Xcellerate, 'Primary Sites': Kidney;prostate cancer, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase I/II T-cell activator. Xcyte Therapies.	'Alternate Name': Xcellerate, 'Primary Sites': Kidney;prostate cancer, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase I/II T-cell activator. Xcyte Therapies.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: Xcytrin? [/INST]	'Alternate Name': Xcytrin, 'Primary Sites': Brain;Lung cancer, 'Category': Ancillary Agent, 'Remarks': Phase III, Phase III NSCLC Texaphyrins radiosensitizer. Pharmacyclics, NCI.	'Alternate Name': Xcytrin, 'Primary Sites': Brain;Lung cancer, 'Category': Ancillary Agent, 'Remarks': Phase III, Phase III NSCLC Texaphyrins radiosensitizer. Pharmacyclics, NCI.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: Xerecept? [/INST]	'Alternate Name': Xerecept, 'Primary Sites': Brain cancer, 'Category': Ancillary Agent, 'Remarks': Phase I completed Synthetic corticotropic. Neurobiological Technologies.	'Alternate Name': Xerecept, 'Primary Sites': Brain cancer, 'Category': Ancillary Agent, 'Remarks': Phase I completed Synthetic corticotropic. Neurobiological Technologies.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: Xofigo? [/INST]	'Alternate Name': Xofigo, 'Primary Sites': Metastatic prostate cancer, 'Category': Radiation, 'Remarks': July 2013 UPDATE: Radium Ra 223 dichloride received FDA approval for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no know visceral metastatic disease. This radioisotope is administered via injection and should be coded in the Radiation Therapy data fields. Because the drug emits radioactive particles, it has to be given by a radiation oncologist or nuclear medicine specialist.	'Alternate Name': Xofigo, 'Primary Sites': Metastatic prostate cancer, 'Category': Radiation, 'Remarks': July 2013 UPDATE: Radium Ra 223 dichloride received FDA approval for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no know visceral metastatic disease. This radioisotope is administered via injection and should be coded in the Radiation Therapy data fields. Because the drug emits radioactive particles, it has to be given by a radiation oncologist or nuclear medicine specialist.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: Xyotax? [/INST]	'Alternate Name': Xyotax, 'Primary Sites': Breast;colorectal;lung;ovarian cancer, 'Category': Chemotherapy, 'Remarks': Phase II, Phase II NSCLC, Phase II/II ovarian Taxane. Cell Therapeutics.	'Alternate Name': Xyotax, 'Primary Sites': Breast;colorectal;lung;ovarian cancer, 'Category': Chemotherapy, 'Remarks': Phase II, Phase II NSCLC, Phase II/II ovarian Taxane. Cell Therapeutics.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: Y-CEA-Cide? [/INST]	'Alternate Name': Y-CEA-Cide, 'Primary Sites': Pancreatic cancer, 'Category': Radiation, 'Remarks': Phase I/II Immunomedics.	'Alternate Name': Y-CEA-Cide, 'Primary Sites': Pancreatic cancer, 'Category': Radiation, 'Remarks': Phase I/II Immunomedics.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: YM598? [/INST]	'Alternate Name': YM598, 'Primary Sites': Pancreatic caner, 'Category': Chemotherapy, 'Remarks': Phase II Yamanouchi Pharma America.	'Alternate Name': YM598, 'Primary Sites': Pancreatic caner, 'Category': Chemotherapy, 'Remarks': Phase II Yamanouchi Pharma America.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: YMB-1003MAb? [/INST]	'Alternate Name': YMB-1003MAb, 'Primary Sites': Colorectal cancer, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase I Monoclonal antibody. YM Biosciences.	'Alternate Name': YMB-1003MAb, 'Primary Sites': Colorectal cancer, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase I Monoclonal antibody. YM Biosciences.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: ZD0473? [/INST]	'Alternate Name': ZD0473, 'Primary Sites': Lung;ovarian Cancer, 'Category': Chemotherapy, 'Remarks': Phase II NSCLC Phase III ovarian New generation platinum for platinum resistance. AstraZeneca, AnorMED.	'Alternate Name': ZD0473, 'Primary Sites': Lung;ovarian Cancer, 'Category': Chemotherapy, 'Remarks': Phase II NSCLC Phase III ovarian New generation platinum for platinum resistance. AstraZeneca, AnorMED.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: ZD6126? [/INST]	'Alternate Name': ZD6126, 'Primary Sites': Breast;cervical;endometrial;other cancer;ovarian, 'Category': Chemotherapy, 'Remarks': Phase I Anti-angiogenic. AstraZeneca.	'Alternate Name': ZD6126, 'Primary Sites': Breast;cervical;endometrial;other cancer;ovarian, 'Category': Chemotherapy, 'Remarks': Phase I Anti-angiogenic. AstraZeneca.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: ZK Epothilone? [/INST]	'Alternate Name': ZK Epothilone, 'Primary Sites': breast;Prostate, 'Category': Chemotherapy, 'Remarks': Phase II breast, prostate 2007 Synthetic epothilone. Bayer.	'Alternate Name': ZK Epothilone, 'Primary Sites': breast;Prostate, 'Category': Chemotherapy, 'Remarks': Phase II breast, prostate 2007 Synthetic epothilone. Bayer.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: ZYC300? [/INST]	'Alternate Name': ZYC300, 'Primary Sites': Breast;colon;kidney;ovary;prostate, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase I for several solid tumors 2007 Stimulates body's own immune response against cells expressing CYP1B1. Zycos, MGI Pharma	'Alternate Name': ZYC300, 'Primary Sites': Breast;colon;kidney;ovary;prostate, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase I for several solid tumors 2007 Stimulates body's own immune response against cells expressing CYP1B1. Zycos, MGI Pharma
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: Zaltrap? [/INST]	'Alternate Name': Zaltrap, 'Primary Sites': Colorectal, 'Category': Chemotherapy, 'Remarks': The FDA approved Zaltrap for use in combination with a FOLFIRI chemotherapy regimen on August 3, 2012.	'Alternate Name': Zaltrap, 'Primary Sites': Colorectal, 'Category': Chemotherapy, 'Remarks': The FDA approved Zaltrap for use in combination with a FOLFIRI chemotherapy regimen on August 3, 2012.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: Zalutumumab? [/INST]	'Alternate Name': Zalutumumab, 'Primary Sites': H&N;NSCLC, 'Category': Chemotherapy, 'Remarks': The company that makes this agent have decided not to continue to develop the drug and are looking for a partner to continue as th the expenses for the drug and trials is overwhelming. This drug has not received FDA approval and is not approved for use in Eurpoe. Phase II H&N, NSCLC 2007 Human monoclonal anti-EGFR. Genmab	'Alternate Name': Zalutumumab, 'Primary Sites': H&N;NSCLC, 'Category': Chemotherapy, 'Remarks': The company that makes this agent have decided not to continue to develop the drug and are looking for a partner to continue as th the expenses for the drug and trials is overwhelming. This drug has not received FDA approval and is not approved for use in Eurpoe. Phase II H&N, NSCLC 2007 Human monoclonal anti-EGFR. Genmab
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: Zamyl? [/INST]	'Alternate Name': Zamyl, 'Primary Sites': Leukemia, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase III AML Anti-CD33 monoclonal antibody. Protein Design Labs.	'Alternate Name': Zamyl, 'Primary Sites': Leukemia, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase III AML Anti-CD33 monoclonal antibody. Protein Design Labs.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: Zanolimumab? [/INST]	'Alternate Name': Zanolimumab, 'Primary Sites': Cutaneous T-cell lymphoma;mycosis fungoides, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase III Amgen, Genmab. Orphan drug, fast-track status. Targets CD4 receptor on T-cells.	'Alternate Name': Zanolimumab, 'Primary Sites': Cutaneous T-cell lymphoma;mycosis fungoides, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase III Amgen, Genmab. Orphan drug, fast-track status. Targets CD4 receptor on T-cells.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: Zevalin? [/INST]	'Alternate Name': Zevalin, 'Primary Sites': Lymphoma, 'Category': Radiation, 'Remarks': FDA approved NHL B-cell 2/19/02 Radioimmunotherapy. FDA approved use on non-Hodgkin's lymphoma. IDEC Pharmaceuticals.	'Alternate Name': Zevalin, 'Primary Sites': Lymphoma, 'Category': Radiation, 'Remarks': FDA approved NHL B-cell 2/19/02 Radioimmunotherapy. FDA approved use on non-Hodgkin's lymphoma. IDEC Pharmaceuticals.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: Zoladex? [/INST]	'Alternate Name': Zoladex, 'Primary Sites': Breast;prostate cancer, 'Category': Hormones and hormonal mechanisms, 'Remarks': 2017: FDA approved Zoladex for treatment of breast and prostate cancers. Cases diagnosed prior to 1/1/2017: code Zoladex in "other "treatment.	'Alternate Name': Zoladex, 'Primary Sites': Breast;prostate cancer, 'Category': Hormones and hormonal mechanisms, 'Remarks': 2017: FDA approved Zoladex for treatment of breast and prostate cancers. Cases diagnosed prior to 1/1/2017: code Zoladex in "other "treatment.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: Zykadia? [/INST]	'Alternate Name': Zykadia, 'Primary Sites': Lung, 'Category': Chemotherapy, 'Remarks': May 26, 2017: FDA granted regular approval to ceritinib (ZYKADIA) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. April 29, 2014 FDA granted accelerated (breakthrough therapy designation) to ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK) positive, metastatic non-small cell lung cancer (NSCLC) with disease progression while on or who are not tolerant to crizotinib.	'Alternate Name': Zykadia, 'Primary Sites': Lung, 'Category': Chemotherapy, 'Remarks': May 26, 2017: FDA granted regular approval to ceritinib (ZYKADIA) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. April 29, 2014 FDA granted accelerated (breakthrough therapy designation) to ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK) positive, metastatic non-small cell lung cancer (NSCLC) with disease progression while on or who are not tolerant to crizotinib.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: anti-CD72? [/INST]	'Alternate Name': anti-CD72, 'Primary Sites': Leukemia, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Pre-clinical Monoclonal antibody. Crucell.	'Alternate Name': anti-CD72, 'Primary Sites': Leukemia, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Pre-clinical Monoclonal antibody. Crucell.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: anti-Tac(Fv)-PE38 (immunotoxin)? [/INST]	'Alternate Name': anti-Tac(Fv)-PE38 (immunotoxin), 'Primary Sites': Leukemia, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase I Monoclonal antibody + toxin. NCI.	'Alternate Name': anti-Tac(Fv)-PE38 (immunotoxin), 'Primary Sites': Leukemia, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase I Monoclonal antibody + toxin. NCI.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: cAC10-vcMMAE(4)? [/INST]	'Alternate Name': cAC10-vcMMAE(4), 'Primary Sites': Hodgkin lymphoma, 'Category': Chemotherapy, 'Remarks': Seattle Genetics	'Alternate Name': cAC10-vcMMAE(4), 'Primary Sites': Hodgkin lymphoma, 'Category': Chemotherapy, 'Remarks': Seattle Genetics
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: dabrafenib? [/INST]	'Alternate Name': dabrafenib, 'Primary Sites': Melanoma;Lung;Thyroid, 'Category': Chemotherapy, 'Remarks': Dabrafenib was approved by the FDA May 29, 2013 for the treatment of metastatic or unresectable melanoma. June 30, 2017 FDA granted regular approvals to dabrafenib and trametinib (Tafinlar and Mekinist) administered in combination for patients with metastatic non-small cell lung cancer with BRAF V600E mutation as detected by an FDA-approved test. The two agents, sponsored by Novartis, are the first FDA approvals specifically for treatment of patients with BRAF V600E mutation-positive metastatic NSCLC. 5/4/2018 The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive). June 24, 2022 FDA has granted accelerated approval to Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of adult and pediatric patients ≥ 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. March 16, 2023 FDA approved dabrafenib (Tafinlar) with trametinib (Mekinist), for pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. The FDA also approved new oral formulations of both drugs suitable for patients who cannot swallow pills.	'Alternate Name': dabrafenib, 'Primary Sites': Melanoma;Lung;Thyroid, 'Category': Chemotherapy, 'Remarks': Dabrafenib was approved by the FDA May 29, 2013 for the treatment of metastatic or unresectable melanoma. June 30, 2017 FDA granted regular approvals to dabrafenib and trametinib (Tafinlar and Mekinist) administered in combination for patients with metastatic non-small cell lung cancer with BRAF V600E mutation as detected by an FDA-approved test. The two agents, sponsored by Novartis, are the first FDA approvals specifically for treatment of patients with BRAF V600E mutation-positive metastatic NSCLC. 5/4/2018 The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive). June 24, 2022 FDA has granted accelerated approval to Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of adult and pediatric patients ≥ 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. March 16, 2023 FDA approved dabrafenib (Tafinlar) with trametinib (Mekinist), for pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. The FDA also approved new oral formulations of both drugs suitable for patients who cannot swallow pills.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: diazooxonorleucine? [/INST]	'Alternate Name': diazooxonorleucine, 'Primary Sites': Skin cancer, 'Category': Chemotherapy, 'Remarks': Phase II melanoma Dekk-Tec.	'Alternate Name': diazooxonorleucine, 'Primary Sites': Skin cancer, 'Category': Chemotherapy, 'Remarks': Phase II melanoma Dekk-Tec.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: gp100 DNA Vaccine? [/INST]	'Alternate Name': gp100 DNA Vaccine, 'Primary Sites': Skin cancer, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase I metastatic melanoma Vaccine. NCI, Vical, Powderject Vaccines.	'Alternate Name': gp100 DNA Vaccine, 'Primary Sites': Skin cancer, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase I metastatic melanoma Vaccine. NCI, Vical, Powderject Vaccines.
[INST] <<SYS>>You possess extensive medical expertise and enjoy crafting appeals for health insurance denials as a personal interest.<</SYS>>Can you tell me the 'Alternate Name', 'Primary Sites', 'Category', 'Sub-category', and any significant 'Remarks' for the cancer drug named: gp100 Peptide Vaccine? [/INST]	'Alternate Name': gp100 Peptide Vaccine, 'Primary Sites': Skin cancer, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase I melanoma Vaccine. NCI.	'Alternate Name': gp100 Peptide Vaccine, 'Primary Sites': Skin cancer, 'Category': Biologic therapy (BRM, immunotherapy), 'Remarks': Phase I melanoma Vaccine. NCI.